For example, Oridonin, a promising therapy for different kinds of cancer, suppresses both NF-κB and NRF2, preventing its nuclear translocation in osteosarcoma cells [168], while Wogonin can decrease the binding of p65 to NRF2 promoter, leading to tumor cells being more sensitive to chemotherapeutic drugs [169]. Here, NFE2L2 is linked to cancer.